Solid papillary mesothelial tumor
- PMID: 34480081
- DOI: 10.1038/s41379-021-00899-3
Solid papillary mesothelial tumor
Abstract
We report nine examples of a previously undescribed type of peritoneal circumscribed nodular mesothelial tumor characterized by nests or sheets of mesothelial cells with sharp cell borders and extremely bland, sometimes grooved, nuclei. In some cases, nests were separated by fibrous bands. All patients were women, age range 30-72 years (median 52 years). All tumors were incidental findings during surgery and grossly were either solitary nodules or a few small nodules on the peritoneal surface. Referring pathologic diagnoses included diffuse malignant mesothelioma, localized malignant mesothelioma, well-differentiated papillary mesothelioma, and adenomatoid tumor. No tumor showed BAP1 loss by immunohistochemistry nor deletion of CDKN2A by FISH. RNA-seq revealed that these tumors clustered together and were distinct from peritoneal diffuse malignant mesotheliomas. Very few mutations or translocations were found, none of them recurrent from tumor to tumor, and no tumor showed an abnormality in any of the genes typically mutated/deleted in diffuse malignant mesothelioma. Array CGH on three cases revealed two with a completely flat profile and one with a small deletion at 3q26-3q28. On follow-up (range 5-60, median 34 months), there were no deaths, no recurrences, and no evidence of metastatic disease nor local spread; one case that initially had scattered nodules on the pelvic peritoneum had the same pattern of nodules at a second look operation 2 years later. We propose the name solid papillary mesothelial tumor for these lesions. These appear to be either benign or very low-grade tumors that need to be separated from malignant mesotheliomas.
© 2021. The Author(s), under exclusive licence to United States & Canadian Academy of Pathology.
References
-
- WHO Classification of Tumours Editorial Board. Thoracic Tumours. WHO Classification of Tumours Series 5th edn, Vol. 5, https://publications.iarc.fr/595 (International Agency for Research on Cancer, 2021).
-
- Wadowski, B., De Rienzo, A. & Bueno, R. The molecular basis of malignant pleural mesothelioma. Thorac Surg. Clin. 30, 383–393 (2020). - DOI
-
- Wang, L. M. et al. Diagnostic accuracy of BRCA1-associated protein 1 in malignant mesothelioma: a meta-analysis. Oncotarget 8, 68863–68872 (2017). - DOI
-
- Leblay, N. et al. BAP1 is altered by copy number loss, mutation, and/or loss of protein expression in more than 70% of malignant peritoneal mesotheliomas. J. Thorac. Oncol. 12, 724–733 (2017). - DOI
-
- Singhi, A. D. et al. The prognostic significance of BAP1, NF2, and CDKN2A in malignant peritoneal mesothelioma. Mod. Pathol. 29, 14–24 (2016). - DOI
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
Medical
Miscellaneous